- Home
- LIPO vs ATXI Comparison
LIPO vs ATXI Comparison
Compare LIPO & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- ATXI
- Stock Information
- Founded
- LIPO 2005
- ATXI 2015
- Country
- LIPO United States
- ATXI United States
- Employees
- LIPO N/A
- ATXI N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- ATXI Health Care
- Exchange
- LIPO Nasdaq
- ATXI Nasdaq
- Market Cap
- LIPO 3.5M
- ATXI 3.0M
- IPO Year
- LIPO 2022
- ATXI 2017
- Fundamental
- Price
- LIPO $2.66
- ATXI $1.84
- Analyst Decision
- LIPO Strong Buy
- ATXI
- Analyst Count
- LIPO 1
- ATXI 0
- Target Price
- LIPO $16.00
- ATXI N/A
- AVG Volume (30 Days)
- LIPO 169.2K
- ATXI 26.2K
- Earning Date
- LIPO 11-14-2024
- ATXI 11-14-2024
- Dividend Yield
- LIPO N/A
- ATXI N/A
- EPS Growth
- LIPO N/A
- ATXI N/A
- EPS
- LIPO N/A
- ATXI N/A
- Revenue
- LIPO $483,533.00
- ATXI N/A
- Revenue This Year
- LIPO N/A
- ATXI N/A
- Revenue Next Year
- LIPO N/A
- ATXI N/A
- P/E Ratio
- LIPO N/A
- ATXI N/A
- Revenue Growth
- LIPO 0.78
- ATXI N/A
- 52 Week Low
- LIPO $2.21
- ATXI $1.60
- 52 Week High
- LIPO $12.00
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- LIPO 45.43
- ATXI 44.82
- Support Level
- LIPO $2.53
- ATXI $1.80
- Resistance Level
- LIPO $2.79
- ATXI $1.88
- Average True Range (ATR)
- LIPO 0.29
- ATXI 0.13
- MACD
- LIPO -0.01
- ATXI -0.01
- Stochastic Oscillator
- LIPO 12.62
- ATXI 40.70
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.